Peptides for Tissue Repair & Healing
NIHR GCP Certified · EUPATI Pharmacovigilance · EUPATI Marketing Authorisations · Johns Hopkins Clinical Trials · FDA CDERLearn
Medically reviewed by a licensed medical professional
8
Compounds
1
Approved
0
In Trials
7
Research
3
Clinical Trials
Tissue repair is the smallest research area on PeptideTrace with just 8 tracked compounds, but it contains two of the most discussed peptides in the entire grey-market space: BPC-157 and TB-500. Both are widely used for injury recovery in athletic and biohacking communities despite having no human clinical trial data from controlled studies.
The one approved compound — palovarotene (Sohonos) — treats a rare genetic condition (fibrodysplasia ossificans progressiva) rather than general tissue repair. It works through retinoid receptor modulation, a different mechanism from the peptides that dominate community discussion.
BPC-157 (body protection compound) is derived from gastric juice proteins and has an extensive preclinical literature across tendon, ligament, muscle, and gut healing models. TB-500 is a synthetic fragment of thymosin beta-4 with animal-model evidence for wound healing and inflammation reduction. Both compounds appear in the immune & anti-inflammatory category as well, reflecting their overlapping mechanisms. The remaining research compounds — ARA-290, cartalax, chonluten, and pentadecapeptide BPC — have more limited evidence bases.
All Compounds
8 compounds tracked in tissue repair & healing. Sort by any column. Filter by classification.
| Compound | Classification | Evidence ↑ | Jurisdictions |
|---|---|---|---|
| Palovarotene | Approved | AGrade A | USEUCA |
| ARA-290 | Research | CGrade C | USEUCA |
| BPC-157 | Research | CGrade C | USEUCA |
| Pentadecapeptide BPC | Research | CGrade C | USEUCA |
| TB-500 | Research | CGrade C | USEUCA |
| Thymosin Beta-4 | Research | CGrade C | USEUCA |
| Cartalax | Research | EGrade E | USEUCA |
| Chonluten | Research | EGrade E | USEUCA |
What the Evidence Shows
Approved Compounds
1 compound in this research area has received regulatory approval in at least one major jurisdiction. These compounds have completed the full regulatory review process, including Phase 3 clinical trials and post-marketing surveillance. Their documented benefits are referenced from licensed labelling only.
Research Compounds
7 compounds in this area exist at the research stage — studied in preclinical settings including animal models and in-vitro experiments, without formal regulatory approval or active clinical programmes. The evidence for these compounds is primarily preclinical, and claims about their effects should be evaluated accordingly.